GenixPharmaceucticals Corporation (GENX) - Net Assets
Based on the latest financial reports, GenixPharmaceucticals Corporation (GENX) has net assets worth CA$-1.47 Million CAD (≈ $-1.06 Million USD) as of January 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CA$35.24K ≈ $25.49K USD) and total liabilities (CA$1.51 Million ≈ $1.09 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Read debt load of GenixPharmaceucticals Corporation for a breakdown of total debt and financial obligations.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CA$-1.47 Million |
| % of Total Assets | -4174.56% |
| Annual Growth Rate | N/A |
| 5-Year Change | -135.36% |
| 10-Year Change | -469.21% |
| Growth Volatility | 53.03 |
GenixPharmaceucticals Corporation - Net Assets Trend (2015–2025)
This chart illustrates how GenixPharmaceucticals Corporation's net assets have evolved over time, based on quarterly financial data. Also explore balance sheet size of GenixPharmaceucticals Corporation for the complete picture of this company's asset base.
Annual Net Assets for GenixPharmaceucticals Corporation (2015–2025)
The table below shows the annual net assets of GenixPharmaceucticals Corporation from 2015 to 2025. For live valuation and market cap data, see market cap of GenixPharmaceucticals Corporation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-10-31 | CA$-1.42 Million ≈ $-1.03 Million |
-19.96% |
| 2024-10-31 | CA$-1.18 Million ≈ $-855.91K |
-4.03% |
| 2023-10-31 | CA$-1.14 Million ≈ $-822.75K |
-135.55% |
| 2022-10-31 | CA$3.20 Million ≈ $2.31 Million |
-20.31% |
| 2021-10-31 | CA$4.01 Million ≈ $2.90 Million |
-17.36% |
| 2020-10-31 | CA$4.86 Million ≈ $3.51 Million |
+11627.99% |
| 2019-10-31 | CA$-42.13K ≈ $-30.48K |
-134.38% |
| 2018-10-31 | CA$122.57K ≈ $88.66K |
+1.32% |
| 2017-10-31 | CA$120.97K ≈ $87.51K |
-68.53% |
| 2016-10-31 | CA$384.43K ≈ $278.09K |
-24.16% |
| 2015-10-31 | CA$506.89K ≈ $366.67K |
-- |
Equity Component Analysis
This analysis shows how different components contribute to GenixPharmaceucticals Corporation's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 866788600.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (October 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | CA$11.12 Million | % |
| Total Equity | CA$-1.42 Million | 100.00% |
GenixPharmaceucticals Corporation Competitors by Market Cap
The table below lists competitors of GenixPharmaceucticals Corporation ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Infinitum Copper Corp
V:INFI
|
$886.71K |
|
Troubadour Resources Inc
V:TR
|
$887.01K |
|
DP Poland Plc
LSE:DPP
|
$889.91K |
|
AOTI Inc
LSE:AOTI
|
$891.93K |
|
Nuwellis Inc
NASDAQ:NUWE
|
$883.35K |
|
Nicolas Miguet et Associes SA
PA:MLNMA
|
$882.96K |
|
Asian Television Network International Ltd
V:SAT
|
$882.63K |
|
Geiger Counter Limited
LSE:GCL
|
$880.13K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in GenixPharmaceucticals Corporation's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from -1,183,200 to -1,419,352, a change of -236,152.
- Net loss of 335,055 reduced equity.
- New share issuances of 100,000 increased equity.
- Other factors decreased equity by 1,097.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CA$-335.06K | -23.61% |
| Share Issuances | CA$100.00K | +7.05% |
| Other Changes | CA$-1.10K | -0.08% |
| Total Change | CA$- | % |
Book Value vs Market Value Analysis
This analysis compares GenixPharmaceucticals Corporation's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-10-31 | CA$0.00 | CA$0.02 | x |
| 2018-10-31 | CA$0.00 | CA$0.02 | x |
| 2019-10-31 | CA$0.00 | CA$0.02 | x |
| 2020-10-31 | CA$0.08 | CA$0.02 | x |
| 2021-10-31 | CA$0.07 | CA$0.02 | x |
| 2022-10-31 | CA$0.05 | CA$0.02 | x |
| 2023-10-31 | CA$-0.02 | CA$0.02 | x |
| 2024-10-31 | CA$-0.02 | CA$0.02 | x |
| 2025-10-31 | CA$-0.02 | CA$0.02 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently GenixPharmaceucticals Corporation utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-29.32%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2015 | -107.71% | -83.89% | 1.05x | 1.22x | CA$-596.67K |
| 2016 | -33.57% | -13.96% | 2.04x | 1.18x | CA$-167.49K |
| 2017 | -201.05% | -24.07% | 2.57x | 3.26x | CA$-255.30K |
| 2018 | 109.39% | 31.92% | 1.81x | 1.89x | CA$121.81K |
| 2019 | 0.00% | -119.87% | 3.41x | 0.00x | CA$-160.49K |
| 2020 | -14.80% | 0.00% | 0.00x | 1.10x | CA$-1.20 Million |
| 2021 | -41.17% | 0.00% | 0.00x | 1.19x | CA$-2.05 Million |
| 2022 | -33.57% | 0.00% | 0.00x | 1.33x | CA$-1.39 Million |
| 2023 | 0.00% | -35600.34% | 0.06x | 0.00x | CA$-4.28 Million |
| 2024 | 0.00% | -1806.86% | 0.09x | 0.00x | CA$45.12K |
| 2025 | 0.00% | 0.00% | 0.00x | 0.00x | CA$-193.12K |
Industry Comparison
This section compares GenixPharmaceucticals Corporation's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $152,180,977
- Average return on equity (ROE) among peers: -69.18%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| GenixPharmaceucticals Corporation (GENX) | CA$-1.47 Million | -107.71% | N/A | $885.77K |
| Aurora Cannabis Inc (ACB) | $1.71 Million | -2.56% | 0.01x | $187.47 Million |
| Amotiv Limited (AOV) | $795.11 Million | 0.54% | 0.21x | $576.83 Million |
| Aequus Pharmaceuticals Inc (AQS) | $-1.38 Million | 0.00% | 0.00x | $479.73K |
| Avicanna Inc (AVCN) | $7.97 Million | -109.67% | 1.76x | $12.74 Million |
| Avant Brands Inc (AVNT) | $49.33 Million | -10.28% | 0.67x | $6.55 Million |
| Bausch Health Companies Inc (BHC) | $260.00 Million | -81.54% | 97.79x | $2.02 Billion |
| CanadaBis Capital Inc (CANB) | $2.85 Million | -315.46% | 0.88x | $1.53 Million |
| Cannabist Company Holdings Inc (CBST) | $266.93 Million | -39.33% | 0.51x | $12.41 Million |
| Cipher Pharmaceuticals Inc (CPH) | $126.01 Million | 22.07% | 0.24x | $318.21 Million |
| Cardiol Therapeutics Inc Class A (CRDL) | $13.27 Million | -155.60% | 0.20x | $146.23 Million |
About GenixPharmaceucticals Corporation
Genix Pharmaceuticals Corporation formulates, manufactures, licenses, and markets life sciences related products with a focus on nutraceuticals and pharmaceuticals in Canada. The company offers generic ophthalmic prescription products, ophthalmic nutraceutical formulations, and prescription generic drugs; ophthalmic OTC products; and eye ointments and drops. It also provides Flu-X, an anti-viral,… Read more